B2B Soft.Tech. (531268)
Fast GrowerScore breakdown: P/E: 2/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 1/1
Key Financials
| Current Price | ₹38.77 |
| Market Cap | ₹45.26 Cr |
| P/E Ratio | 14.75 |
| ROCE | 15.2% |
| ROE | 13.2% |
| Dividend Yield | 2.55% |
| Profit Growth | 90.77% |
| Debt/Equity | — |
| Sales Growth | 53.33% |
| 52-Week Range | ₹15.81 — ₹38.77 |
| Sector | IT - Software |
| Book Value | ₹16.54 |
Strengths
- Sales growth of 53.33% and profit growth of 90.77% show strong momentum.
- P/E of 14.75 with PEG of 0.20 suggests attractive valuation relative to growth.
- Piotroski F-Score of 7/9 indicates solid financial health signals.
- ROE of 13.20% and ROCE of 15.20% reflect reasonable capital efficiency.
- Dividend yield of 2.55% provides some shareholder return while growing.
Concerns
- Very small base: market cap of only ₹45 Cr and quarterly net profit of ₹1 Cr leaves little room for error.
- Promoter holding is not disclosed, making insider alignment unclear.
- Debt/Equity is N/A, so leverage and balance-sheet risk cannot be assessed.
- Stock is trading at its 52-week high with P/B of 2.34, offering limited margin of safety.
AI Analysis
At ₹38.77, this is a tiny ₹45 crore software products business. On the surface, it displays the kind of growth that makes an investor stop and look twice: sales up 53.33% and profits up 90.77%. A P/E of 14.75 with a PEG of 0.20 suggests the market is not paying enough for that growth — if it is durable. The Piotroski F-score of 7 out of 9 gives me some comfort on financial health, and a 2.55% dividend yield while growing is a rare combination. Still, I must be cautious. A ₹1 crore quarterly profit on ₹8 crore quarterly sales is thin; at this size, one lost client or a failed product cycle can damage the economics. ROE of 13.20% and ROCE of 15.20% are respectable, but not extraordinary, and a price-to-book of 2.34 means I am paying a meaningful premium over book value. The absence of promoter holding data troubles me. As Graham taught, management’s skin in the game matters enormously, especially in small caps. Also, with debt/equity marked as not available, the true balance-sheet risk remains unknown. The stock sits at the top of its 52-week range at ₹38.77, which tests my discipline — I much prefer buying with a margin of safety. This looks like a fast grower, but the key question is whether growth is sustainable and can convert into scale. I would not chase it blindly. I would wait for more evidence: continued quarterly momentum, better disclosure on capital structure, and visible promoter commitment. If those confirm, this could deserve a deeper look. But at this price, patience and verification are essential.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer